Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Given Average Rating of “Moderate Buy” by Analysts

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) has been assigned an average recommendation of “Moderate Buy” from the seven research firms that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, three have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $44.25.

Several brokerages have commented on DMRA. Leerink Partners assumed coverage on shares of Damora Therapeutics, Inc. Common Stock in a research report on Wednesday, January 7th. They issued an “outperform” rating and a $46.00 price objective on the stock. Zacks Research upgraded shares of Damora Therapeutics, Inc. Common Stock to a “hold” rating in a research note on Friday, January 9th. UBS Group initiated coverage on shares of Damora Therapeutics, Inc. Common Stock in a report on Tuesday, February 17th. They issued a “buy” rating and a $45.00 price target on the stock. Guggenheim reiterated a “buy” rating and issued a $40.00 price objective (up from $36.00) on shares of Damora Therapeutics, Inc. Common Stock in a research note on Tuesday, February 17th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Damora Therapeutics, Inc. Common Stock in a report on Monday, December 29th.

Damora Therapeutics, Inc. Common Stock Stock Performance

Shares of NASDAQ:DMRA opened at $25.50 on Friday. The company has a market capitalization of $1.54 billion, a P/E ratio of -2.11 and a beta of 1.42. The company’s 50-day moving average is $27.02 and its 200 day moving average is $19.77. Damora Therapeutics, Inc. Common Stock has a fifty-two week low of $2.01 and a fifty-two week high of $38.33.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Two Sigma Investments LP bought a new stake in Damora Therapeutics, Inc. Common Stock in the 3rd quarter valued at about $76,000. Virtu Financial LLC purchased a new stake in Damora Therapeutics, Inc. Common Stock during the third quarter valued at about $49,000. Connective Capital Management LLC bought a new position in Damora Therapeutics, Inc. Common Stock during the third quarter worth about $100,000. Sigma Planning Corp purchased a new position in shares of Damora Therapeutics, Inc. Common Stock in the fourth quarter worth about $334,000. Finally, Geode Capital Management LLC purchased a new position in shares of Damora Therapeutics, Inc. Common Stock in the fourth quarter worth about $266,000. Institutional investors own 14.20% of the company’s stock.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.